Clinical study of some traditional medicines for the treatment of ischemic heart disease (TMK00.2)
- VernacularTitle:Зүрхний хий хатгалга өвчинд (TMK00.2) уламжлалт анагаах ухааны зарим эм хэрэглэсэн эмнэлзүйн судалгаа
- Author:
Bolor
1
,
2
;
Nasandalai
2
;
Alimaa T
1
Author Information
1. Department of Mongolian Medicine Study, International School of Mongolian Medicine, MNUMS
2. International Medical Committee of Inner Mongolia
- Publication Type:Clinical Trial
- Keywords:
Chronic coronary syndromes;
Traditional medicine;
Quality of life;
Clinical trial
- From:
Mongolian Journal of Health Sciences
2025;88(4):117-121
- CountryMongolia
- Language:Mongolian
-
Abstract:
Background:In traditional Mongolian medicine, ischemic heart disease are treated by balancing the body, promoting the
f
low of khii and blood, improving the metabolism, suppressing inflammation, increasing heart strength, relieving pain,
and treating the disease according to its actual condition. Therefore, a study was conducted to investigate the effects of
traditional medicines Heart Agar-8 and Zandan-3 on ischemic heart disease.
Aim:Studying the therapeutic effects of some traditional medicines used in the treatment of ischemic heart disease.
Materials and Methods:Clinical trial was performed in an uncontrolled, single-centered, and open-study design. A total
of 48 patients with ischemic heart disease who met the inclusion criteria participated in the study. The study was conduct
ed by giving people 3 grams of Heart Agar-8 and 3 grams of Zandan-3 medicine, each once a day, for a total of 3 weeks.
The results of the study were assessed before and after the study using the SAQ questionnaire, the chronic coronary syn
dromes (CCS) questionnaire, 6-minute walk test, and electrocardiogram. The research was conducted in accordance with
the appropriate ethical approvals (No. 24-25/03-01), (No. 2024-077) and confirmed by an informed consent form. Clinical
trial research results were processed using T-test, Paired T-test.
Results:A total of 48 people diagnosed with ischemic heart disease (TMK00.2) were included in the study. The average
age of the study participants was 53.94±1.69, with the youngest being 44 and the oldest being 60. Regarding the gender
of the respondents, 15 (31.25%) were men and 33 (68.75%) were women. When comparing pre-treatment results with
post-treatment results using the SAQ, there were improvements in mobility (p<0.000), chest stability (p<0.012), chest
pain (p<0.000), treatment satisfaction (p<0.001), and quality of life assessment (p<0.000). When assessing chronic cor
onary syndrome in people, 44 or 91.6% of the total number of people included in the study had a level II score before
treatment, while 37 or 77.08% had a level I score after treatment, which was a statistically significant difference between
the pre-treatment and post-treatment indicators (p<0.034). Cardiac function was assessed by the 6-minute walk test,
which was 393.9±36.73 meters before treatment, or grade II, but improved to 456.83±48.6 meters after treatment, or grade
I (p<0.000).
Conclusions: 1. People diagnosed with ischemic heart disease have shown statistically significant results when given the traditional
medicine Heart Agar-8 and Zandan-3 in combination with clinical trials.
2. The study participants experienced statistically significant improvements in mobility, usual activities, pain, and
depression, improved quality of life, and increased functional status in coronary heart disease.
- Full text:2025052211393969328117-121.pdf
